Annals ofRheumatoid Arthritis
Volume: 2 - Number: 12 - June 15, 2004
In this issue
- Acid uric
- ANCA vasculitis
- Ankylossing spondylitis and TNFalfa- blokers
- Chronic pain
- Ciclooxigenase and prostanoid
- Incliximab and tuberculosis
- Juvenile idiopathic arthritis
- Lupus
- Mortality vs, quolity of life
- Osteoarthritis
- Rheumatoid Arthritis
- Rheumatoid arthritis and TNFalfa- blockers
- Scleroderma
- Scleroderma?
- Self management
- Therapeutics
- TNF alfa-blockers and consensus
- Traumatology for clinician
Outstanding
Rheumatoid Arthritis—A Molecular Understanding
Rheumatoid Arthritis: Is the Disease Becoming Milder or Is Treatment Improving?
Treatment of Refractory Juvenile Idiopathic Arthritis
Tumor Necrosis Factor Inhibitors "SPARCC" an Interest in Consensus
Acid uric
When, Why, and How Should We Quantify the Excretion Rate of Urinary Uric Acid?
ANCA vasculitis
Treatment of ANCA-Associated Vasculitis
Ankylossing spondylitis and TNFalfa- blokers
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor
Chronic pain
Coping with Chronic Pain: What Can We Learn from Pain Self-Efficacy Beliefs?
Ciclooxigenase and prostanoid
Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways
Incliximab and tuberculosis
Tuberculosis and Treatment with Infliximab
Juvenile idiopathic arthritis
Treatment of Refractory Juvenile Idiopathic Arthritis
Uveitis Associated with Juvenile Idiopathic Arthritis: Envisioning the Future
Lupus
Who Should Look After Patients with Mild Lupus?
Mortality vs, quolity of life
Treatment Related Mortality versus Quality of Life -- A Balancing Act
Osteoarthritis
What Does Cartilage Calcification Tell Us About OA?
Rheumatoid Arthritis
Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis—A Molecular Understanding
Is There a Rationale for Switching from One Anti-Tumor Necrosis Factor Agent to Another?
Rheumatoid Arthritis: Is the Disease Becoming Milder or Is Treatment Improving?
What I Would Like to Know About Leflunomide
Rheumatoid arthritis and TNFalfa- blockers
Treating rheumatoid arthritis with tumour necrosis factor alfha blockade
Scleroderma
When Is Scleroderma Really Scleroderma?
Scleroderma?
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Self management
WOMAC: A 20-Year Experiential Review of a Patient-Centered Self-Reported Health Status Questionnaire
Therapeutics
Hypertension, Nonsteroidal Antiinflammatory Drugs, and Lessons Learned
TNF alfa-blockers and consensus
Tumor Necrosis Factor Inhibitors "SPARCC" an Interest in Consensus
